Evidence map›Paper›PMID 40826900›Full record

ArticleBritish journal of haematology2025

Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A NOPHO-DBH AML study.

Morten Krogh Herlin, Eigil Kjeldsen, Jonas Abrahamsson, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Kirsi Jahnukainen, Ólafur Gísli Jónsson, Gertjan J L Kaspers, Zhanna Kovalova and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Morten Krogh HerlinDepartment of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Eigil KjeldsenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jonas AbrahamssonDepartment of Paediatrics, Institution for Clinical Sciences, Queen Silvia Children's Hospital, Gothenburg, Sweden.
Nira Arad-CohenDepartment of Paediatric Haemato-Oncology, Rambam Medical Centre, Haifa, Israel.
Daniel CheukHong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG), Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, China.
Barbara De MoerlooseDepartment of Paediatric Haematology-Oncology, Ghent University Hospital, Ghent, Belgium.
Kirsi JahnukainenNew Children's Hospital, Paediatric Research Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ólafur Gísli JónssonDepartment of Paediatrics, Landspitalinn, Reykjavik, Iceland.
Gertjan J L KaspersEmma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Zhanna KovalovaDepartment of Paediatric Oncology/Haematology, Children's Clinical University Hospital, Riga, Latvia.
Jose Maria Fernandez NavarroHospital Universitario y Politécnico La Fe, Valencia, Spain.
Ulrika Noren-NyströmDepartment of Paediatrics, Umeå University Hospital, Umeå, Sweden.
Josefine PalleDepartment of Woman's and Children's Health, Uppsala University, Uppsala, Sweden.
Ramunė PasaulienėCentre of Oncohaematology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Kadri SaksDepartment of Paediatrics, Tallinn, Estonia.
Bernward ZellerDivision of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0001-9008-4495
Linda HolmfeldtDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Henrik HasleDepartment of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Kristian Løvvik Juul-DamDepartment of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0003-0028-8115

Funding

Graduate School of Health, Aarhus UniversityHealth Research Foundation of Central Denmark Region A1055Kom op tegen KankerThe Danish Childhood Cancer Foundation 2015-5The Danish Childhood Cancer Foundation 2018-3729
6 · The paper itself

Abstract

Normal karyotype acute myeloid leukaemia (NK-AML) in children is a heterogeneous subgroup with scarce data on characteristics and prognosis. We investigated NK-AML in a large paediatric AML cohort from four trials of the Nordic Society for Paediatric Haematology and Oncology-Dutch Belgian Hongkong (NOPHO-DBH) group. Among 1476 AML patients, we identified 316 NK-AML patients (21%). NK-AML was characterized by high frequencies of FLT3 internal tandem duplications (ITD, 33%), mutated NPM1 (28%), WT1 (25%) and CEBPA (21%). Five-year event-free survival (EFS) and overall survival (OS) in NK-AML were 52% (95% confidence interval [CI]: 46-58) and 70% (CI: 65-75) respectively. Restricted to NPM1

Indexed as

Leukemia, Myeloid, AcuteAdolescentCCAAT-Enhancer-Binding ProteinsChildChild, PreschoolFemalefms-Like Tyrosine Kinase 3HumansInfantKaryotypeMaleMutationNuclear ProteinsNucleophosminPrognosisCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminacute myeloid leukaemiachildhoodcytogenetics of leukaemiaprognostic factors

Identifiers

PMID40826900
PMCPMC12512081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.